|Cell Line Name:||Saos-2|
|Keywords:||Human primary osteogenic sarcoma|
|Cell Line Description:||Reported to have been derived from an 11 year old female Caucasian. The patient was treated with RTG, methotrexate, adriamycin, vincristine, cytoxan, and aramycin-C. HLA cell line phenotype: A2,3;Bw16,w47.|
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 1-4x10,000 cells/cmÂ² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37Â°C.|
|Culture Medium:||McCoy's 5a + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Karyotype:||2n = 46, (P1) Hyperploid to hypopentaploid|
|References:||Fogh J/ Trempe G (1975) In; Human Tumour Cells In Vitro (ed) Fogh J, Plenum Press, NY pp115-159; J Nat Cancer Inst 1977;58:209; J Nat Cancer Inst 1977;59:221|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Research Council Deposit:||No|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.